vs

Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and Rhinebeck Bancorp, Inc. (RBKB). Click either name above to swap in a different company.

AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $13.5M, roughly 1.5× Rhinebeck Bancorp, Inc.). Rhinebeck Bancorp, Inc. runs the higher net margin — 17.3% vs -541.1%, a 558.4% gap on every dollar of revenue. On growth, Rhinebeck Bancorp, Inc. posted the faster year-over-year revenue change (1701.1% vs 86.1%). Rhinebeck Bancorp, Inc. produced more free cash flow last quarter ($10.9M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 14.0%).

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

Rhinebeck Bancorp, Inc. is a US regional bank holding company based in New York. It operates Rhinebeck Bank, offering retail and commercial banking services including deposit accounts, loans, mortgages and wealth management, mainly serving consumers and small-to-medium businesses across New York's Hudson Valley region.

AGIO vs RBKB — Head-to-Head

Bigger by revenue
AGIO
AGIO
1.5× larger
AGIO
$20.0M
$13.5M
RBKB
Growing faster (revenue YoY)
RBKB
RBKB
+1615.0% gap
RBKB
1701.1%
86.1%
AGIO
Higher net margin
RBKB
RBKB
558.4% more per $
RBKB
17.3%
-541.1%
AGIO
More free cash flow
RBKB
RBKB
$108.2M more FCF
RBKB
$10.9M
$-97.3M
AGIO
Faster 2-yr revenue CAGR
AGIO
AGIO
Annualised
AGIO
56.1%
14.0%
RBKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGIO
AGIO
RBKB
RBKB
Revenue
$20.0M
$13.5M
Net Profit
$-108.0M
$2.3M
Gross Margin
90.6%
Operating Margin
-608.9%
21.7%
Net Margin
-541.1%
17.3%
Revenue YoY
86.1%
1701.1%
Net Profit YoY
-11.9%
188.0%
EPS (diluted)
$-1.86
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGIO
AGIO
RBKB
RBKB
Q4 25
$20.0M
$13.5M
Q3 25
$12.9M
$14.0M
Q2 25
$12.5M
$13.1M
Q1 25
$8.7M
$12.8M
Q4 24
$10.7M
$750.0K
Q3 24
$9.0M
$773.0K
Q2 24
$8.6M
$10.7M
Q1 24
$8.2M
$10.4M
Net Profit
AGIO
AGIO
RBKB
RBKB
Q4 25
$-108.0M
$2.3M
Q3 25
$-103.4M
$2.7M
Q2 25
$-112.0M
$2.7M
Q1 25
$-89.3M
$2.3M
Q4 24
$-96.5M
$-2.7M
Q3 24
$947.9M
$-8.1M
Q2 24
$-96.1M
$975.0K
Q1 24
$-81.5M
$1.1M
Gross Margin
AGIO
AGIO
RBKB
RBKB
Q4 25
90.6%
Q3 25
87.0%
Q2 25
86.3%
Q1 25
87.6%
Q4 24
88.3%
Q3 24
91.3%
Q2 24
82.6%
Q1 24
92.3%
Operating Margin
AGIO
AGIO
RBKB
RBKB
Q4 25
-608.9%
21.7%
Q3 25
-907.4%
23.9%
Q2 25
-1020.1%
26.6%
Q1 25
-1222.0%
22.9%
Q4 24
-1165.3%
-444.9%
Q3 24
-1146.9%
-1332.3%
Q2 24
-1228.3%
11.8%
Q1 24
-1124.3%
13.9%
Net Margin
AGIO
AGIO
RBKB
RBKB
Q4 25
-541.1%
17.3%
Q3 25
-803.1%
19.3%
Q2 25
-899.4%
20.8%
Q1 25
-1023.3%
17.9%
Q4 24
-899.6%
-353.9%
Q3 24
10574.7%
-1042.9%
Q2 24
-1115.7%
9.2%
Q1 24
-995.8%
10.8%
EPS (diluted)
AGIO
AGIO
RBKB
RBKB
Q4 25
$-1.86
$0.21
Q3 25
$-1.78
$0.25
Q2 25
$-1.93
$0.25
Q1 25
$-1.55
$0.21
Q4 24
$-1.44
$-0.24
Q3 24
$16.22
$-0.75
Q2 24
$-1.69
$0.09
Q1 24
$-1.45
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGIO
AGIO
RBKB
RBKB
Cash + ST InvestmentsLiquidity on hand
$89.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$136.9M
Total Assets
$1.3B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGIO
AGIO
RBKB
RBKB
Q4 25
$89.1M
Q3 25
$92.7M
Q2 25
$80.9M
Q1 25
$79.0M
Q4 24
$76.2M
Q3 24
$253.7M
Q2 24
$84.5M
Q1 24
$118.8M
Stockholders' Equity
AGIO
AGIO
RBKB
RBKB
Q4 25
$1.2B
$136.9M
Q3 25
$1.3B
$133.0M
Q2 25
$1.4B
$129.0M
Q1 25
$1.5B
$126.0M
Q4 24
$1.5B
$121.8M
Q3 24
$1.6B
$122.7M
Q2 24
$660.5M
$116.2M
Q1 24
$743.9M
$114.3M
Total Assets
AGIO
AGIO
RBKB
RBKB
Q4 25
$1.3B
$1.3B
Q3 25
$1.4B
$1.3B
Q2 25
$1.5B
$1.3B
Q1 25
$1.6B
$1.3B
Q4 24
$1.7B
$1.3B
Q3 24
$1.8B
$1.3B
Q2 24
$773.1M
$1.3B
Q1 24
$849.7M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGIO
AGIO
RBKB
RBKB
Operating Cash FlowLast quarter
$-96.2M
$11.7M
Free Cash FlowOCF − Capex
$-97.3M
$10.9M
FCF MarginFCF / Revenue
-487.5%
80.6%
Capex IntensityCapex / Revenue
5.6%
6.3%
Cash ConversionOCF / Net Profit
5.03×
TTM Free Cash FlowTrailing 4 quarters
$-377.3M
$19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGIO
AGIO
RBKB
RBKB
Q4 25
$-96.2M
$11.7M
Q3 25
$-88.2M
$2.2M
Q2 25
$-77.1M
$2.4M
Q1 25
$-111.5M
$4.3M
Q4 24
$-133.2M
$8.5M
Q3 24
$-84.2M
$-3.6M
Q2 24
$-72.6M
$12.0M
Q1 24
$-99.9M
$-3.5M
Free Cash Flow
AGIO
AGIO
RBKB
RBKB
Q4 25
$-97.3M
$10.9M
Q3 25
$-89.7M
$2.0M
Q2 25
$-78.0M
$2.2M
Q1 25
$-112.3M
$4.2M
Q4 24
$-134.1M
$7.7M
Q3 24
$-84.6M
$-3.6M
Q2 24
$-72.7M
$11.8M
Q1 24
$-100.0M
$-3.7M
FCF Margin
AGIO
AGIO
RBKB
RBKB
Q4 25
-487.5%
80.6%
Q3 25
-696.5%
14.5%
Q2 25
-626.2%
17.2%
Q1 25
-1286.4%
32.8%
Q4 24
-1250.1%
1023.9%
Q3 24
-944.2%
-469.0%
Q2 24
-844.4%
111.1%
Q1 24
-1221.2%
-36.0%
Capex Intensity
AGIO
AGIO
RBKB
RBKB
Q4 25
5.6%
6.3%
Q3 25
12.1%
1.4%
Q2 25
7.0%
1.4%
Q1 25
8.8%
0.9%
Q4 24
9.0%
105.5%
Q3 24
4.7%
6.3%
Q2 24
1.8%
1.2%
Q1 24
1.7%
2.3%
Cash Conversion
AGIO
AGIO
RBKB
RBKB
Q4 25
5.03×
Q3 25
0.83×
Q2 25
0.89×
Q1 25
1.89×
Q4 24
Q3 24
-0.09×
Q2 24
12.27×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons